Digestive Diseases and Sciences

, Volume 51, Issue 12, pp 2270–2273

Randomized, Single-Blind, Placebo-Controlled Multicenter Trial to Compare the Efficacy and Safety of Metronidazole and Satranidazole in Patients With Amebic Liver Abscess

  • Jameel Muzaffar
  • Kaushal Madan
  • M. P. Sharma
  • Premashish Kar
Original Paper

Abstract

The aims of our randomized, single-blind trial involving 49 patients were to study the efficacy, side effects, and tolerance of metronidazole and satranidazole in patients of amebic liver abscess. Twenty-five patients received metronidazole (800 mg TID) and 24 received satranidazole (300 mg TID with placebo at mealtime). Patients recorded side effects and tolerability through a performa. The time taken for resolution of fever and pain and the fall in abscess size was not significant. However, tolerance of satranidazole as reported by the patients was significantly better than metronidazole (P < .005). The incidence of adverse effects was significantly lower in the group given satranidazole (P < .005). The incidence of nausea and metallic taste was significantly lower in the patients given satranidazole (P < .005). Thus, despite having a similar efficacy, satranidazole showed a far lower incidence of side effects and had a significantly better tolerance than Metronidazole.

Keywords

Hepatic amebiasis Metronidazole Satranidazole Randomized control trial 

References

  1. 1.
    Nair MD, Nagarajan K (1983) Nitroimidazoles as chemotherapeutic agents. In: Jucker E (ed) Progress in drug research, Vol 27. Birkhauser Verlag, Basel, pp 163–252Google Scholar
  2. 2.
    Ray DK, Tendulkar JS, Shrivastava VB, Nagarajan K (1982) Comparative efficacy of Metronidazole and other 5-nitroimidazole, in cecal amebiasis in albino mice (Mus musculus). J Antimicrob Chemother 10:355–357CrossRefPubMedGoogle Scholar
  3. 3.
    Ray DK, Shrivastava VB, Tendulkar JS, Dutta AK, Bhopale KK, Chatterjee DK, Nagarajan K (1983) Comparative studies on the amebicidal activity of known 5-nitroimidazole derivatives and CG-10213-Go in golden hamsters, Mesocricetus auratus, infected in the liver or caecum or both with trophozoites of Entamoeba histolytica. Ann Trop Med Parasitol 77:287–291PubMedGoogle Scholar
  4. 4.
    Zahoor A, Knight RC, Whitty P, Edwards DI (1986) Satranidazole: mechanism of action on DNA and structure-activity correlations. J Antimicrob Chemother 18:17–25CrossRefPubMedGoogle Scholar
  5. 5.
    Powell SJ, Wilmot AJ, MacLeod I, et al. (1966) Metronidazole in amebic dysentery and amebic liver abscess. Lancet 2:1329–1331CrossRefPubMedGoogle Scholar
  6. 6.
    Simjee AE, Gathiram V, Jackson TFHG, Khan BFY (1985) A comparative trial of Metronidazole v. tinidazole in treatment of amebic liver abscess. S Afr Med J 68:923–924PubMedGoogle Scholar
  7. 7.
    Bhatia S, Karnad DR, Loak J (1998) Randomized double-blind trial of Metronidazole versus secnidazole in amebic liver abscess. Ind J Gastroenterol 17:53–54Google Scholar
  8. 8.
    Pargal A, Rao C, Bhopale KK, Pradhan KS, Masani KB, Kaul CL (1993) Comparative pharmacokinetics and amebicidal activity of Metronidazole and Satranidazole in the golden hamsters, Mesocricetus auratus. J Antimicrob Chemother 32:483–489CrossRefPubMedGoogle Scholar
  9. 9.
    Gadgil SD, Vaidya AB, Talwalkar S, Doshi B, Kulkarni RD (1984) The absence of interaction of a new anti-protozoal agent Go. 10213 Cibemone. J Assoc Physicians India 32:705–708PubMedGoogle Scholar

Copyright information

© Springer Science&#x002B;Business Media, Inc. 2006

Authors and Affiliations

  • Jameel Muzaffar
    • 1
  • Kaushal Madan
    • 2
  • M. P. Sharma
    • 2
  • Premashish Kar
    • 3
  1. 1.Department of MedicineMaulana Azad Medical College and Lok Nayak HospitalNew DelhiIndia
  2. 2.All India Institute of Medical SciencesNew DelhiIndia
  3. 3.Maulana Azad Medical College and Lok Nayak HospitalNew DelhiIndia

Personalised recommendations